ARCHIVES

ODAC Meets at ASCO, Recommends Approval Of Dasatinib For CML.

This article is from The Cancer Letter archive.

Vol. 32 No. 22 | June 9, 2006

Download PDF Visit The Full Archive

Related Articles

Hammer Says He’ll Demand Construction Funds If Data Supports The Need

August 12, 1983

Spending Measures Include Provisions On Ethics For NIH Extramural Scientists.

July 11, 2008

Ilex Oncology Buys Symphar, Controls Drug For Bone Mets.

March 2, 2001

Cancer Mortality Rate Down 1.3 Percent, ACS Report Finds

July 30, 2010

HPV Vaccines Should Be Priority, Say President’s Cancer Panel

March 7, 2014

Cancer Policy: EMFs “Possible” Carcinogen, Panel Says; Plans Public Hearings

August 7, 1998